Journal
ANNALS OF GASTROENTEROLOGICAL SURGERY
Volume 6, Issue 1, Pages 17-28Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/ags3.12526
Keywords
circulating tumor DNA; colorectal cancer; genetics; targeted therapy
Categories
Funding
- National Institutes of Health [P50 CA174521-01]
Ask authors/readers for more resources
Advances in understanding the genetic basis of colorectal cancer have led to pre-symptomatic detection and targeted therapy, with the introduction of circulating tumor DNA into patient management showing promise in changing treatment paradigms.
Knowledge of the genetic basis of colorectal cancer has evolved over the past decades, allowing for the pre-symptomatic identification of affected patients in those with familial syndromes and to the understanding of the multi-step progression to carcinogenesis in tumors. Knowledge of the genes and pathways involved in colorectal cancer has allowed for targeted therapies in patients in addition to standard chemotherapy for those with metastases. Next-generation sequencing technologies have now also allowed for the sensitive detection of circulating mutations derived from tumors, which can give insight into the presence of residual disease and has implications for changing the standard paradigms for treatment. This article will specifically review advances in targeted therapy in metastatic colon cancer and the progress being made in using circulating tumor DNA in patient management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available